SINGAPORE - People who are eligible for the Novavax Covid-19 vaccine can go to selected clinics from Jan 24 to April 30 for ...

Moderna stock surged Wednesday after Oracle Chairman Larry Ellison praised the potential of AI in developing medicines.

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...

Moderna's technology focuses on helping the body create specific messenger RNA, or mRNA. When the mRNA sees ... Moderna sells ...

Dr. Paul Hunter, a professor of medicine at Britain’s University of East Anglia, described the mRNA vaccines made by BioNTech-Pfizer and Moderna Inc. as a “game changer” in shutting down the ...

The Louisiana Department of Health noted yesterday that a 65-year-old hospital patient had died due to bird flu.

The first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines.

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

Both the Moderna and Pfizer/BioNTech actions are being heard in a Delaware district court. The lawsuits contribute to an ongoing bun fight between various parties involved in mRNA vaccines ...

We have seen encouraging data with Moderna’s personalised melanoma vaccine and BioNTech is due to present data on its mRNA-shared antigen melanoma vaccine at ESMO. At Circio, we are developing a ...